Trial · NCT02452346

Study of Clinical Efficacy and Safety of Tosedostat in MDS

NCT02452346, Phase 2, Completed, Weill Medical College of Cornell University; results first posted 2018-06-12

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. Study of Clinical Efficacy and Safety of Tosedostat in MDS. Trials, record NCT02452346. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02452346

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Clinical Efficacy and Safety of Tosedostat in MDS
NCT number: NCT02452346
Status: Completed
Phases: Phase 2
Enrollment: 12 participants, actual
Lead sponsor: Weill Medical College of Cornell University
Conditions: Myelodysplastic Syndrome
Interventions: Tosedostat
First posted: 2015-05-22
Last updated: 2018-06-12
Results first posted: 2018-06-12

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Over All Survival	from start of treatment until death, assessed up to a period of 3-4 years.	Survival following treatment to the date of death, assessed up to a period of 3-4 years.
Secondary	Overall Response	Approximately 3 years	Overall response according to IWG 2006 criteira
Secondary	One Year and Two Year Survival	from start of treatment to 1 year and 2 years post treatment initiation

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Over All Survival	from start of treatment until death, assessed up to a period of 3-4 years.	months	MEDIAN
SECONDARY	Overall Response	Approximately 3 years	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	One Year and Two Year Survival	from start of treatment to 1 year and 2 years post treatment initiation	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Over All Survival	All Patients		15.9	Full Range 2.5 to 30.7	months
Overall Response	All Patients	Complete Remission	1		Participants
Overall Response	All Patients	Stable Disease	8		Participants
Overall Response	All Patients	Non-evaluable	3		Participants
One Year and Two Year Survival	All Patients	One year survival	8		Participants
One Year and Two Year Survival	All Patients	two year survival	4		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	All Patients	12
Overall Study	COMPLETED	All Patients	3
Overall Study	NOT COMPLETED	All Patients	9

Source ClinicalTrials.gov

Adverse events78

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Other - BNP increased	Investigations	All Patients	7	12
other	Electrocardiogram QT corrected interval prolonged	Investigations	All Patients	6	12
other	Fatigue	General disorders	All Patients	6	12
other	Bruising	Injury, poisoning and procedural complications	All Patients	5	12
other	Diarrhea	Gastrointestinal disorders	All Patients	5	12
other	Edema limbs	General disorders	All Patients	5	12
other	Hypomagnesemia	Investigations	All Patients	4	12
other	Alanine transferase increased	Investigations	All Patients	3	12
other	Dizziness	Nervous system disorders	All Patients	3	12
other	Dry skin	Skin and subcutaneous tissue disorders	All Patients	3	12

1 to 10 of 78Source ClinicalTrials.gov

See all 78 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	All Patients	9	12
Total, other adverse events	All Patients	12	12
Total, serious adverse events	All Patients	8	12

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
33043735	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release: trials-2026-11-12-0.4.0
Release manifest SHA-256: 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture: 2026-11-12
Results copy, AACT: 2026-03-23
NIH clinical studies file: 2026-11-13

Source ClinicalTrials.gov

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02452346

GET https://conductscience.org/api/trials/v1/NCT02452346/events?page=2

API reference For AI assistants